Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of MEDI9929 in Adults with Severe Asthma
2013-003269-33Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing MEDI9929 with Placebo (2 arms). Primary endpoint: Annualized asthma exacerbation rate at Week 52. Started Nov 2013; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on 2013-003269-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003269-33.